Myeloma Kidney Therapy

A new lifeline for myeloma kidney patients Even as they fight their cancer, multiple myeloma patients can be forced to face an unwelcome effect of their condition—the serious risk of acute and chronic renal failure. A new therapy under evaluation can help them combat renal impairment and perhaps add a few more—and better—years of life with their families.

Fighting cancer—and renal failure
Multiple myeloma is a serious and chronic illness. But often renal failure— as a further consequence of their disease—drastically worsens the patient’s condition and shortens the time they have left. Renal failure is caused by an unwelcome by-product of myeloma—
unmanageable quantities of Free Light Chain (FLC) proteins.

A new option for Free Light Chain removal
Until now, there has been little success in attempts to use blood purification
techniques to remove these damaging molecules, and stop them disrupting
the kidneys. But the new Myeloma Kidney Therapy made possible by Gambro
could be a lifeline for many of these patients.

More time for patients and their families?
Initial pilot studies of the new therapy, as well as predictions derived from
modeled survival data, point to long-term clinical benefits and a cost-effective
use of healthcare resources in comparison with historical controls.1,2,3,7 The
difference for patients and their families can be measured in months and even
years. These findings are currently being validated in an on-going randomized
controlled trial.

 

A therapy for myeloma kidney patients is now available. Thanks to the emergence of an innovative, new technology from Gambro.

A combination of effective chemotherapy, FLC removal and monitoring
Initial studies show that the solution for these patients with acute renal failure is Myeloma Kidney Therapy:
• Effective chemotherapy to reduce the number of malignant, FLC-secreting plasma cells
• Efficient direct removal of FLCs from the serum
• Accurate and rapid monitoring of FLC levels to ensure optimized treatment (see end of brochure for     details on Freelite™ immunodiagnostic assays)

In combination: Myeloma Kidney Therapy


       Chemotherapy  Freelite™        

Theralite™
High Cut-off technology

Theralite™ High Cut-off technology
It is with a new technology for the efficient and direct removal of FLCs that Gambro has been able to provide the missing ingredient. Theralite™ High Cut-off technology is uniquely successful in removing FLCs because its large pores do not restrict removal.

Rapid reduction in serum FLC concentrations
Clinical studies report very positive results for Myeloma Kidney Therapy. Through the combination of direct removal using Theralite and effective chemotherapy, FLC levels are rapidly reduced.




Ordering information

Please contact us to order Theralite™ High Cut-off technology or receive more information: partner@gambro.com